The E100: Biotech execs are bullish about 2017, but fret about drug pricing and the FDA under Trump
About the Endpoints 100: This is our second biotech industry survey, which we sent out to our invite-only group of executives on February 6. 98 execs, primarily in the US and Europe, completed the survey, You can see a list of the entire group at the end of this article.
The biotech industry is feeling bullish about its own prospects at the beginning of 2017, largely satisfied with the financial support that’s been flowing in to the field with most execs ready to hire through the year as the tempo on deal-making remains upbeat.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.